Ghalaut Veena S, Prakash Gulshan, Bansal Piyush, Dahiya Kiran, Dokwal Sumit, Ghalaut Pratap S, Bala Manju, Dhankhar Rakesh
Department of Biochemistry, Pt. B.D. Sharma PGIMS, Rohtak, Haryana, India.
Department of Biochemistry, Pt. B.D. Sharma PGIMS, Rohtak, Haryana, India
J Oncol Pharm Pract. 2014 Aug;20(4):243-8. doi: 10.1177/1078155213500686. Epub 2013 Aug 21.
Multiple animal studies, few clinical case reports and one study have observed decreased testosterone production and gynaecomastia as adverse effect of imatinib therapy. We have prospectively studied testosterone, LH and FSH levels at baseline and at 6 months of imatinib treatment in 34 newly diagnosed male BCR-ABL positive CML patients. While none of the patients had gynaecomastia at 6 months, the proportion of patients with low testosterone level increased significantly from 11.8% at baseline to 58.8% (p < 0.001) and those with high LH and FSH increased significantly from 26.4% and 23.5% to 82.4% and 76.4%, respectively (p < 0.001 and p < 0.001). Serum testosterone levels decreased significantly (p = 0.002) and serum LH and FSH levels increased significantly at 6 months of imatinib therapy (p = 0.001 and p = 0.003) in comparison to baseline levels. The findings document the effect of imatinib on testosterone levels in adult CML patients much before than reported earlier.
多项动物研究、少数临床病例报告以及一项研究观察到，伊马替尼治疗的不良反应包括睾酮生成减少和男性乳房发育。我们前瞻性地研究了34例新诊断的男性BCR-ABL阳性慢性粒细胞白血病（CML）患者在基线时以及伊马替尼治疗6个月时的睾酮、促黄体生成素（LH）和促卵泡生成素（FSH）水平。虽然6个月时没有患者出现男性乳房发育，但睾酮水平低的患者比例从基线时的11.8%显著增加到58.8%（p<0.001），LH和FSH水平高的患者比例分别从26.4%和23.5%显著增加到82.4%和76.4%（p<0.001和p<0.001）。与基线水平相比，伊马替尼治疗6个月时血清睾酮水平显著降低（p=0.002），血清LH和FSH水平显著升高（p=0.001和p=0.003）。这些发现证明，伊马替尼对成年CML患者睾酮水平的影响比之前报道的要早得多。
